SITC 2022 | Landscape analysis of neoepitope-specific T-cell responses depending on clinical benefit from ICIs

Cristina Puig Saus, PhD, University of California, Los Angeles, talks on the landscape analysis of the neoepitope-specific T-cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy. 11 patients with melanoma treated with anti-PD1 alone or in combination with other immune checkpoint blockade and divided into responders and non-responders to therapy. Neoepitope-specific T-cells and tumor-infiltrating lymphocytes were isolated from the blood samples taken at baseline and throughout the course of treatment. The antigens being targeted were identified, as well as the sequence of the T-cell receptor (TCR) generating these antigens. Only a small number of antigens are being targeted in both responders and non-responders, however, the T-cells in responders are polyclonal, so there are different T-cells with different TCR sequences that target the same mutations. T-cells in non-responders were not polyclonal. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.